“BrightFocus is highly encouraged by Biogen’s announcement today that clinical trials of its experimental drug aducanumab reduced cognitive decline in some Alzheimer’s patients through improved cognition, memory, and activities of daily living.
This news is a powerful reminder that research equals hope, no matter how daunting the medical and scientific challenge. The teaming up of innovative researchers and dedicated clinical trial volunteers can lead to life-changing breakthroughs.
BrightFocus, through its Alzheimer’s Disease Research program, helped lay the groundwork for possible treatments like this, and while there is still a long way to go in ending this disease, this is a truly promising development.”
The information provided in this section is a public service of BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.